2016
DOI: 10.5500/wjt.v6.i3.564
|View full text |Cite
|
Sign up to set email alerts
|

Updates on antibody-mediated rejection in intestinal transplantation

Abstract: Antibody-mediated rejection (ABMR) has increasingly emerged as an important cause of allograft loss after intestinal transplantation (ITx). Compelling evidence indicates that donor-specific antibodies can mediate and promote acute and chronic rejection after ITx. However, diagnostic criteria for ABMR after ITx have not been established yet and the mechanisms of antibody-mediated graft injury are not well-known. Effective approaches to prevent and treat ABMR are required to improve long-term outcomes of intesti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(10 citation statements)
references
References 52 publications
(63 reference statements)
0
10
0
Order By: Relevance
“…Antibody mediated rejection (AMR) is a major contributor to rejection risk and allograft loss in solid organ transplantation [ 1 , 2 ]. AMR diagnostic criteria were first established in cardiac [ 3 ] and renal [ 4 ] transplantation and have recently been described for pancreas [ 5 ] and lung transplantation [ 6 ] and, although historically controversial, are proposed for liver [ 7 ] and intestinal [ 8 ] allografts as well. AMR incidence is approximately 10–20% in cardiac [ 9 ], 5–8% in renal [ 10 ], 4–25% in lung [ 11 , 12 ], and 24% in liver [ 13 ] transplant.…”
Section: Introductionmentioning
confidence: 99%
“…Antibody mediated rejection (AMR) is a major contributor to rejection risk and allograft loss in solid organ transplantation [ 1 , 2 ]. AMR diagnostic criteria were first established in cardiac [ 3 ] and renal [ 4 ] transplantation and have recently been described for pancreas [ 5 ] and lung transplantation [ 6 ] and, although historically controversial, are proposed for liver [ 7 ] and intestinal [ 8 ] allografts as well. AMR incidence is approximately 10–20% in cardiac [ 9 ], 5–8% in renal [ 10 ], 4–25% in lung [ 11 , 12 ], and 24% in liver [ 13 ] transplant.…”
Section: Introductionmentioning
confidence: 99%
“… Although feasibility studies into the role of molecular and biomarker profiling of inflammation in the context of the transplant pancreas have been reported, this is currently an area of potential development, rather than yet having a recognized diagnostic role, as for example is seen in kidney transplantation . Histological features of duodenal rejection, especially antibody‐mediated, remain relatively poorly defined, potentially making it difficult to identify duodenal rejection as an underlying cause for duodenal leaks . This may explain why duodenal rejection was not identified in explanted grafts with duodenal leaks that had histological evidence of APR.…”
Section: Discussionmentioning
confidence: 99%
“…The histological criteria for a diagnosis of acute cellular rejection (ACR) were as described previously [ 22 ]. A diagnosis of acute antibody-mediated rejection (ABMR) is based on clinical evidence of graft dysfunction, high PRA levels with circulating donor-specific antibody (DSA) and pathological evidence of tissue injury and C4d deposition [ 23 ]. A new rejection episode is defined as the occurrence of new clinical symptoms with characteristic pathologies and at least one normal mucosal biopsy between two rejection events.…”
Section: Methodsmentioning
confidence: 99%